TransMedics Q2 revenue rises 38% to $157.4 million; raises 2025 guidance
TransMedics reported second-quarter 2025 revenue of $157.4 million, up 38% from $114.3 million a year earlier, and net income of $34.9 million, or $0.92 per diluted share, versus $12.2 million in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $585 million to $605 million from the prior range of $565 million to $585 million, which is the main development for shareholders.
Key points
- Q2 2025 total revenue was $157.4 million, up 38% from $114.3 million in Q2 2024
- Q2 2025 net income was $34.9 million, or $0.92 per diluted share, compared with $12.2 million, or $0.35 per diluted share, a year earlier
- Full-year 2025 revenue guidance raised to $585 million to $605 million from $565 million to $585 million
- Gross margin was 61%, consistent with the prior-year quarter; operating expenses rose to $60.0 million from $56.8 million
The filing
Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.